Abstract: A system and method for identifying potential targets for a pharmaceutical compound. The system includes a database arrangement operable to store existing data sources and information related to the pharmaceutical compound; and a processing module communicably coupled to database arrangement. The processing module is operable to receive information related to the pharmaceutical compound, wherein the information includes at least one known target associated with the pharmaceutical compound; extract plurality of targets from existing data sources, wherein the existing data sources comprise plurality of data records and wherein each of the plurality of targets is associated with the pharmaceutical compound in at least one data record; analyse druggability of each of plurality of targets to determine a preliminary set of targets; determine net score for each of the targets in preliminary set of targets; and designate targets with a net score above a predefined threshold, as potential targets.

Abstract: An approach is disclosed for mapping biomedical entities, wherein each of the biomedical entities belong to one of a predefined class: target, disease, pathway, and drug. The system comprises a database arrangement operable to store existing data sources; a processing module communicably coupled to the database arrangement. The processing module operable to receive a user-input of a biomedical entity belonging to one of the predefined classes, wherein the predefined class of the biomedical entity defines an input class. Extract a plurality of biomedical entities related to the biomedical entity of the user-input from existing data sources, wherein the plurality of biomedical entities belong to predefined classes except the input class. Identify at least one pair of biomedical entities, from the plurality of extracted biomedical entities, having an association there between and map the plurality of biomedical entities to the biomedical entity of the user-input.

Abstract: Disclosed is a system for gaining mechanistic insights into action of a drug using in-silico techniques. The system is communicably coupled to a phenotype ontological databank; wherein the system comprises a processor communicably coupled to a memory. The processor is configured to receive a first input of the drug, receive a second input relating to at least one phenotype associated with the drug, identify targets of the drug to obtain a drug target list, determine phenotypic targets of the drug, compare the drug target list with the phenotypic targets of the drug to identify a plurality of overlapping targets therebetween, generate a Drug-Target-Phenotype (DTP) network using the plurality of overlapping targets, compute relevant pathways by performing Signaling Pathway Impact Analysis (SPIA) for the plurality of overlapping targets, generate a Pathway-Target-Phenotype (PTP) network, and compute mechanistic insights into the action of the drug from the analysis of PTP network.

Abstract: A computer program product and corresponding computer-implemented method cause the performance of various operations to upgrade a network storage device having first and second storage controllers operating in an active-passive mode and disk media shared by the storage controllers. The first storage controller operating as a passive storage controller is caused to enter a new IQN for each virtual disk into a first iSCSI target configuration file and maintain a corresponding old IQN. The first storage controller is then caused to begin operating as the active storage controller so that the second storage controller, while operating as the passive storage controller, is caused to enter the new IQN for each virtual disk into a second iSCSI target configuration file and maintain the corresponding old IQN. Accordingly, the first and second iSCSI target configuration files map both the old and new IQNs to the virtual disks.

Abstract: A computer program product and a data storage device including first and second storage controllers operating in active-passive mode with a shared disk. Each storage controller includes a storage device storing program instructions and a processor to process the program instructions and perform various operations. The operations include receiving a task to be performed by the storage device containing the first and second storage controllers, wherein the first storage controller is currently operating as an active storage controller and the second storage controller is currently operating as a passive storage controller. The operations further include determining whether the received task has a high priority or a low priority, performing the received task in response to determining that the received task has a high priority, and delegating the received task to the second storage controller for performance in response to determining that the received task has a low priority.

Abstract: A system for screening phenotypic targets associated with a disease using in-silico techniques. The system communicably coupled to a phenotype ontological databank including a plurality of phenotypes and phenotypic targets associated with each of the plurality of phenotypes; wherein the system includes a processor communicably coupled to a memory.

Abstract: A system for enabling in-silico phenotypic screening of drugs, the system is communicably coupled to a phenotype ontological databank. The system include a processor communicably coupled to a memory.

Abstract: A pharmaceutical composition comprising an effective amount of Dacomitinib as epidermal growth factor receptor (EGFR) inhibitor and a prostaglandin-Endoperoxide Synthase 2 (PTGS2) inhibitor, and one or more pharmaceutically acceptable excipients. A pharmaceutical composition comprising an effective amount of Dacomitinib as epidermal growth factor receptor (EGFR) inhibitor and an Adrenoceptor Beta 2 (ADRB2) inhibitor, and one or more pharmaceutically acceptable excipients. A method of treating pancreatic cancer, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition to an individual in need thereof, the pharmaceutical composition comprising an effective amount of Dacomitinib as epidermal growth factor receptor (EGFR) inhibitor with a prostaglandin-Endoperoxide Synthase 2 (PTGS2) inhibitor or an Adrenoceptor Beta 2 (ADRB2) inhibitor, and one or more pharmaceutically acceptable excipients.

Abstract: A system for generating drug compositions for a disease target, the system comprises a database arrangement and a processor, wherein the processor is configured to receive information comprising one or more drugs associated with the disease target, identify a plurality of parameters associated with the disease target, using the database arrangement, construct a matrix to identify at least one of direct and indirect synergies of each of the drug with the plurality of parameters and assign weights thereby to each of the parameters with respect to each of the drug, based on the identified at least one of direct and indirect synergies, calculate a total score of each of the drug and rank the plurality of drugs based on the calculated total score and sort thereby the plurality of drugs. The processor then determines the one or more potential drug compositions on the basis of the sorted plurality of drugs.

Abstract: A phosphoinositide 3-kinase inhibitor for use in the treatment of pancreatic cancer and a method for treatment of pancreatic cancer including administration of an phosphoinositide 3-kinase inhibitor an Src inhibitor to a human subject in need thereof. There is also provided a pharmaceutical composition comprising a phosphoinositide 3-kinase inhibitor and an Src inhibitor.

Abstract: A method for evaluating potential drug compositions for a target disease. The method includes providing a data input to a discovery engine, using the discovery engine to identify a first set of potential drug compositions for the target disease. The discovery engine is configured to analyze failed clinical assets of drugs for the target disease, wherein the discovery engine filters clinical trials which have failed due to non-drug safety related issues, perform differential gene expression analysis on normalized target-disease-related data, evaluate effect of known drugs used for diseases similar to the target disease, and perform a network-based analysis to identify repurposable drugs. Furthermore, asset prioritization is used to filter the first set of potential drug compositions to determine at least one potential drug composition for the target disease and validating the at least one potential drug composition for the target disease based on biological evidence and differential expression analysis.

Abstract: A method for determining combination drug and use in pancreatic cancer treatment, includes retrieving Pancreatic cancer datasets from a plurality of data sources based on selected types of expression profiling. A set of feature genes is determined based on differential gene expression analysis of disease samples and control samples in normalized pancreatic cancer datasets. Pancreatic cancer targets are selected for combination analysis based on druggability and determined set of feature genes. Based on node embedded clustering of the selected pancreatic cancer targets, synergistic target pairs is determined. Candidate pairs of drug combinations are selected from a plurality of pairs of drug combinations based on cumulative ranking score of each pair of drug combination and the synergistic target pairs.

Abstract: A phosphoinositide 3-kinase inhibitor for use in the treatment of pancreatic cancer and a method for treatment of pancreatic cancer including administration of an phosphoinositide 3-kinase inhibitor an Src inhibitor to a human subject in need thereof. There is also provided a pharmaceutical composition comprising a phosphoinositide 3-kinase inhibitor and an Src inhibitor.

Abstract: A method for selection of a set of candidate drug compounds includes generating a plurality of knowledge-based pathways based on at least relevant information. The relevant information is extracted from structured information based on an ontology of interest. A set of target structures is identified based on the plurality of knowledge-based pathways. A plurality of candidate drug compounds is determined for the identified set of target structures. Based on safety analysis of the plurality of candidate drug compounds using a lethality index, a set of candidate drug compounds is selected from the plurality of candidate drug compounds.

Abstract: A system and method of mapping biomedical entities, wherein each of the biomedical entities belong to one of a predefined class: target, disease, pathway, and drug. The system includes a database arrangement operable to store existing data sources; a processing module communicably coupled to the database arrangement. The processing module operable to receive a user-input of a biomedical entity belonging to one of the predefined classes, wherein the predefined class of the biomedical entity defines an input class; extract a plurality of biomedical entities related to the biomedical entity of the user-input from existing data sources, wherein the plurality of biomedical entities belong to predefined classes except the input class; identify at least one pair of biomedical entities, from the plurality of extracted biomedical entities, having an association therebetween; and map the plurality of biomedical entities to the biomedical entity of the user-input.

Abstract: A system and method for identifying potential targets for a pharmaceutical compound. The system includes a database arrangement operable to store existing data sources and information related to the pharmaceutical compound; and a processing module communicably coupled to database arrangement. The processing module is operable to receive information related to the pharmaceutical compound, wherein the information includes at least one known target associated with the pharmaceutical compound; extract plurality of targets from existing data sources, wherein the existing data sources comprise plurality of data records and wherein each of the plurality of targets is associated with the pharmaceutical compound in at least one data record; analyse druggability of each of plurality of targets to determine a preliminary set of targets; determine net score for each of the targets in preliminary set of targets; and designate targets with a net score above a predefined threshold, as potential targets.

Abstract: A user interface to a software installer is arranged to enable users to select additional software products that are downloaded, queued, and then installed dynamically (i.e., “on-the-fly”) on a PC while an existing software installation is performed. The user interface may be configured to provide an indication of the progress of software products that are currently being installed, as well as a list of other software products that are available for installation. When a user selects a new software product from the list, the installer will immediately fetch the software and queue it for installation. The user interface will be updated to display the installation progress for the new software product along with the installation progress for the existing products. The user can repeat the process and continue to add new products that will also be installed on-the-fly until all the desired software products are installed on the user's PC.

Abstract: A method and apparatus to decrease the amount of time it takes to obtain friendly names of Bluetooth devices is presented. A name server caches friendly names for devices that it has acquired from other devices or from other name servers. The name server is any device that caches friendly names of Bluetooth devices and that makes the friendly names available to other devices. A requesting device determines if a name server has responded to an inquiry command. If a name server has responded, the device gets the friendly names the name server has cached and requests the friendly names of devices that responded that have not been cached by the name server. Identification of a name server is accomplished by embedding a marker in the friendly name field after the null character to indicate that the device is a name server.